Aeglea Bio Therapeutics Inc.

12/06/2021 | Press release | Distributed by Public on 12/06/2021 05:33

Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency